SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

12 May 2025 Evaluate
The revenue for the March 2025 quarter is pegged at Rs. 1560.02 millions against Rs. 1638.17 millions recorded during the year-ago period.The Total Profit for the quarter ended March 2025 of Rs. 114.51 millions grew from Rs.-114.61 millionsOperating Profit reported a sharp decline to 230.91 millions from 336.13 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 1560.02 1638.17 -4.77 6672.05 6054.60 10.20 6672.05 6054.60 10.20
Other Income 93.61 84.64 10.60 362.16 335.01 8.10 362.16 335.01 8.10
PBIDT 230.91 336.13 -31.30 1278.02 1406.68 -9.15 1278.02 1406.68 -9.15
Interest 13.00 15.31 -15.09 65.84 58.06 13.40 65.84 58.06 13.40
PBDT 217.91 -90.04 -342.01 1212.18 937.76 29.26 1212.18 937.76 29.26
Depreciation 74.35 62.29 19.36 270.47 235.19 15.00 270.47 235.19 15.00
PBT 143.56 -152.33 -194.24 941.71 702.57 34.04 941.71 702.57 34.04
TAX 29.05 -37.72 -177.01 252.03 196.13 28.50 252.03 196.13 28.50
Deferred Tax -10.44 -97.62 -89.31 -47.89 -75.49 -36.56 -47.89 -75.49 -36.56
PAT 114.51 -114.61 -199.91 689.68 506.44 36.18 689.68 506.44 36.18
Equity 105.37 104.69 0.65 105.37 104.69 0.65 105.37 104.69 0.65
PBIDTM(%) 14.80 20.52 -27.86 19.15 23.23 -17.55 19.15 23.23 -17.55

Bliss GVS Pharma Share Price

262.90 -6.05 (-2.25%)
24-Apr-2026 10:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1627.45
Dr. Reddys Lab 1313.00
Cipla 1289.70
Zydus Lifesciences 927.90
Lupin 2300.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×